Finance Manager, R&D Consolidations
Gilead Sciences
Summary
The Finance Manager, R&D Consolidations will own and drive integrated financial processes spanning month-end close, management reporting, and short-term planning for R&D. This role combines rigorous accounting and reporting execution with forward-looking planning, analysis, and business partnership. The position requires the ability to manage complex, cross-functional deliverables, synthesize portfolio-level financial results, and translate key drivers into clear insights for senior leadership.
Job description
Core Responsibilities
- Manage and lead the overall month-end close and short-term planning processes, including forecast, budget, and quarterly landing estimates across R&D Finance
- Own the end-to-end R&D Finance planning calendar across month-end close, budget, and forecast; drive short-term planning processes and coordinate assumptions and submissions across R&D finance stakeholders and Corporate FP&A
- Lead month-end close process for R&D Finance, including management review meetings, the R&D Close Package for Corporate, IPE, audit-driven deliverables, and SEC reporting support
- Collaborate cross-functionally with FP&A, Controllership, and other partners to manage close timelines, communicate deliverables, resolve issues, and deliver accurate and timely reporting
- Synthesize key financial drivers and develop clear R&D commentary and executive-level presentations for Corporate reporting, short-term planning reviews, leadership reviews, and external reporting considerations
- Perform annual industry benchmarking analysis, in addition to leading ad hoc and other special projects
- Proactively identify and implement process improvements that increase the efficiency, consistency, control, and effectiveness of close, reporting, analysis, and planning processes
Basic Qualifications
Bachelor's Degree and Six Years' Experience OR Masters' Degree and Four Years' Experience
Preferred Qualifications
- Minimum of 6 years of progressive finance experience, or 4 years with an MBA, with increasing scope and responsibility
- Experience managing complex cross-functional processes and influencing stakeholders without direct authority
- Prior experience in biotechnology or pharmaceuticals is strongly preferred
- Strong knowledge of accounting and finance, including U.S. GAAP, financial controls, close processes, forecasting, and variance analysis
- Extract, analyze, reconcile, and report financial data from ERP and planning systems with a high degree of accuracy and technical expertise
- Experience in a high-growth, multinational organization is a plus
- Familiarity with Six Sigma, Lean, process mapping, or similar operational improvement methods is a plus; advanced certification such as PMP is also a plus
Requirements
- Bachelor's Degree and Six Years' Experience OR Masters' Degree and Four Years' Experience
- Minimum of 6 years of progressive finance experience, or 4 years with an MBA
- Experience managing complex cross-functional processes and influencing stakeholders without direct authority
- Strong knowledge of accounting and finance, including U.S. GAAP, financial controls, close processes, forecasting, and variance analysis
- Extract, analyze, reconcile, and report financial data from ERP and planning systems
- Prior experience in biotechnology or pharmaceuticals is strongly preferred
- Familiarity with Six Sigma, Lean, process mapping, or similar operational improvement methods is a plus
- Advanced certification such as PMP is a plus
Benefits
- Medical, Dental & Vision
- Life Insurance
- Paid Time Off
- Annual Bonus
- Stock-Based Long-Term Incentives
Company overview
Gilead Sciences, Inc. is a leading American biopharmaceutical company headquartered in Foster City, California, that specializes in researching, developing, and commercializing innovative medicines for life-threatening diseases. Founded in 1987, Gilead has grown into a global healthcare leader with approximately 17,600 employees worldwide. The company's primary therapeutic focus areas include HIV/AIDS, viral hepatitis (hepatitis B and C), oncology, inflammation, and respiratory diseases. Gilead is renowned for its groundbreaking antiviral therapies, including Sovaldi and Harvoni for hepatitis C, and its comprehensive portfolio of HIV treatments such as Truvada, Atripla, and Biktarvy. The company also developed Veklury (remdesivir) for COVID-19 treatment. Gilead operates as a publicly traded company on the NASDAQ (GILD) and is a component of both the Nasdaq-100 and S&P 100 indices. Through strategic acquisitions like Kite Pharma and Immunomedics, Gilead has expanded into cell therapy and oncology, demonstrating its commitment to advancing medical science and improving patient outcomes globally.